METHODS: We identified men age>65 diagnosed with prostate cancer from [2004][2005][2006][2007][2008][2009][2010][2011][2012][2013] in the SEER-CAHPS database. SEER-CAHPS combines cancer registry data with Medicare claims and CAHPS surveys, which captures patient-reported health and care experience. For each patient, we measured baseline demographics, cancer characteristics, claims-based health status (eg, Charlson Comorbidity Index [CCI], Function-Related Indicators), and patientreported health status (eg, overall, mental, and functional health). We then constructed 5 models composed of different data types: 1) demographics; 2) demographics and cancer data; 3) demographics, cancer data, and claims-based health status; 4) demographics, cancer data, and patient-reported health status; and 5) all categories. For each model, we performed competing risk regression and evaluated the discriminatory ability of each model to predict other cause mortality by comparing the area under the receiver operator curve (AUC).
INTRODUCTION AND OBJECTIVES: Shared decision-making (SDM) to guide treatment of localized prostate cancer requires delivery of the anticipated quality of life (QOL) outcomes of contemporary treatment options (including robotic prostatectomy [RP] , radiation therapy [RT] and active surveillance [AS] ). We sought to create a tool to predict personalized sexual, urinary, bowel, and hormonal function outcomes after RP, RT and AS.
METHODS: The CEASAR Study is a multicenter, prospective, observational study of men diagnosed with localized prostate cancer from 2011 to 2012. 2,138 men were followed from enrollment to 5 years with the Expanded Prostate Cancer Index short form (EPIC-26). Responses to the 26 questions are aggregated into 5 domain scores (sexual, urinary irritative, urinary incontinence, bowel, hormonal) . Comprehensive models to predict domain scores were fit, including all available covariates (age, race, pre-treatment PSA, biopsy grade, BMI, EPIC-26 baseline function, treatment, and scores measuring comorbidity, general QOL and psychosocial health.) We fit parsimonious models for each domain with factors selected based on clinical considerations and statistical performance. The parsimonious and comprehensive models were compared using a 300-iteration bootstrap approach. Adjusted Rsquared values were compared and calibration plots developed to evaluate the performance of the parsimonious models versus the comprehensive models. A web-based tool was developed from the parsimonious models.
RESULTS: The prediction models achieved adjusted Rsquared values of 0.388, 0.245, 0.217, 0.234, and 0.348 for sexual function, urinary incontinence, urinary irritative, bowel, and hormonal domains, respectively. Differences in R-squared values between the comprehensive and parsimonious models were small in magnitude and not statistically significant. Calibration was excellent ( Figure 1 ). The web-based tool may be found at https://statez.shinyapps.io/ PCDSPred/.
CONCLUSIONS: Functional outcomes after treatment for localized prostate cancer can be predicted at the time of diagnosis based on age, race, PSA, biopsy grade, baseline function, and a general question regarding overall health. Providers and patients can use this prediction tool to inform SDM.
INTRODUCTION AND OBJECTIVES:
Dual eligible beneficiaries, those that qualify for Medicare based on age and Medicaid due to low income, are a particularly vulnerable population with much to gain from efforts to improve quality. Integrated delivery systems (IDS), with their emphasis on care coordination and communication, may help improve quality of care for dual eligible patients at the end of life. Our objective is to define the quality of care for dual eligible patients with urological malignancies at the end of life across various delivery systems.
METHODS: We used Surveillance, Epidemiology and End Results registry data linked with Medicare claims to evaluate quality for beneficiaries who died from bladder, kidney or prostate cancer and were diagnosed from 2008 through 2013. We evaluated adherence to seven nationally endorsed end of life quality measures according to patient's dual eligible status and receipt of care in an IDS using generalized linear models. We compared end of life quality measure performance for dual eligible and non-dual eligible beneficiaries, and for dual eligible patients in IDS and non-IDS.
RESULTS: Among 11,703 beneficiaries who died from prostate, kidney or bladder cancer during the study interval, we identified inferior outcomes for dual eligible beneficiaries across nearly every quality measure assessed (Figure) . Compared to non-dual eligible beneficiaries, dual eligible patients were more likely to have >1 hospitalization (12.3% vs 10.6%), were more likely to die in a hospital setting (25.8% vs 23.3%) and have multiple ED visits (15.8% vs 12.5%), all p<0.05). We noted no differences in quality measure performance for dual eligible patients treated in IDS versus non-IDS.
CONCLUSIONS: Dual eligible status is associated with inferior quality measure performance at the end of life for patients with genitourinary malignancies. These disparities were not dampened by receipt of care in an IDS. These findings suggest targeted efforts may be needed to optimize quality at the end of life for this group of vulnerable patients who face unique socioeconomic challenges. INTRODUCTION AND OBJECTIVES: Guidelines recommend life expectancy (LE) calculation as a critical tool to inform treatment decisions in prostate cancer (PCa). Overtreatment of candidates for watchful waiting (WW) is multifactorial and includes patient preferences, physician risk tolerance, and disease characteristics. We aimed to determine the rates of WW vs. treatment in favorable-risk PCa (FRPCa) and limited LE and assess determinants of treatment.
METHODS: Patients with <10 years LE were identified from the prospective Michigan Urological Surgery Improve Collaborative (MUSIC) PCa registry. LE was calculated as described by Cho et al. Binary and multinomial logistic regression models were used to compare factors associated with management (WW vs. active surveillance (AS) vs. definitive treatment; WW vs. any other management) in FRPCa. Data from high-volume practices (n>30) was analyzed to understand practice variation. FRPCa was defined as Gleason Grade (GG) 1 or low-volume GG 2 (1-3 cores positive, no core with 3þ4 >50%).
RESULTS: A total of 2,393 patients were included. Across all risk categories, WW was performed in only 8.1%, while 23.3%, 25%, 11.2%, 3.5%, and 28.9% underwent AS, external beam radiation therapy (EBRT), radical prostatectomy (RP), brachytherapy (BT), or other treatments, respectively. In men with NCCN low-risk PCa (n[358), WW was performed in only 15%, compared to AS (69.3%), EBRT (4.2%), RP (6.7%), and BT (2.5%). In FRPCa (n[704), there was wide practice-level variation; WW (3.3%-33.3%), AS (44.4%-73.3%), and definitive treatment (21.9%-46.7%) (p[0.019) [ Figure 1 ]. Higher GG (OR 0.17, p<0.001), cT2 or higher stage (OR 0.57, p[0.03) 
